Brief: Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor Cdi-988 Into Phase 1 Multiple-Ascending Dose Cohorts
26/09/2024 13:15
Sept 26 (Reuters) - Cocrystal Pharma Inc COCP.O :
* COCRYSTAL PHARMA ADVANCES ORAL PAN-VIRAL PROTEASE
INHIBITOR
CDI-988 INTO PHASE 1 MULTIPLE-ASCENDING DOSE COHORTS
* COCRYSTAL PHARMA INC: TOPLINE STUDY RESULTS ARE EXPECTED
IN LATE
2024 OR EARLY 2025
Source text for Eikon: ID:nGNX9TN0Xy
Further company coverage: COCP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cocrystal Pharma
See all newsBrief: Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment
Cocrystal Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Cocrystal Pharma Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway